Literature DB >> 1587753

Patterns of recurrence of malignant astrocytoma following stereotactic interstitial brachytherapy with iodine-125 implants.

C B Agbi1, M Bernstein, N Laperriere, P Leung, M Lumley.   

Abstract

The pattern of tumor recurrence was studied in a series of 68 patients who were treated with interstitial brachytherapy for malignant astrocytoma. Thirty-six patients had newly diagnosed tumors and were treated following surgery and external beam therapy, while 32 were treated for recurrent tumors. Recurrence pattern was determined using computed tomography at the time of clinical deterioration. Thirty-eight percent of tumor recurrence occurred within the original tumor margin and 50% occurred at the original site but extended beyond the initial margin. In all, 88.0% recurred at the initial tumor site, 71.4% being confined to within 2 cm of the pretreatment tumor borders while 6.0% recurred intracranially outside of the initial tumor margin. One patient recurred with spinal metastasis while two patients developed systemic metastases. The significance of these findings is discussed.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1587753     DOI: 10.1016/0360-3016(92)90748-7

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  10 in total

1.  Interstitial fluid flow along white matter tracts: a potentially important mechanism for the dissemination of primary brain tumors.

Authors:  C P Geer; S A Grossman
Journal:  J Neurooncol       Date:  1997-05       Impact factor: 4.130

Review 2.  Interstitial brachytherapy and hyperthermia for malignant gliomas.

Authors:  P H Gutin; D C Shrieve; D A Larson; P Sneed
Journal:  J Neurooncol       Date:  1993-08       Impact factor: 4.130

3.  Adenoviral vector-mediated gene transfer: timing of wild-type p53 gene expression in vivo and effect of tumor transduction on survival in a rat glioma brachytherapy model.

Authors:  J Bampoe; J Glen; S L Hubbard; B Salhia; P Shannon; J Rutka; M Bernstein
Journal:  J Neurooncol       Date:  2000-08       Impact factor: 4.130

Review 4.  Brachytherapy for brain tumors.

Authors:  Todd W Vitaz; Peter C Warnke; Viviane Tabar; Philip H Gutin
Journal:  J Neurooncol       Date:  2005-05       Impact factor: 4.130

5.  Permanent iodine 125 brachytherapy in patients with progressive or recurrent glioblastoma multiforme.

Authors:  David A Larson; Jeffrey M Suplica; Susan M Chang; Kathleen R Lamborn; Michael W McDermott; Penny K Sneed; Michael D Prados; William M Wara; M Kelly Nicholas; Mitchel S Berger
Journal:  Neuro Oncol       Date:  2004-04       Impact factor: 12.300

Review 6.  Hypofractionated radiotherapy for glioblastoma: strategy for poor-risk patients or hope for the future?

Authors:  M Hingorani; W P Colley; S Dixit; A M Beavis
Journal:  Br J Radiol       Date:  2012-09       Impact factor: 3.039

7.  Neuroimaging classification of progression patterns in glioblastoma: a systematic review.

Authors:  Rory J Piper; Keerthi K Senthil; Jiun-Lin Yan; Stephen J Price
Journal:  J Neurooncol       Date:  2018-03-30       Impact factor: 4.130

Review 8.  The role of imaging in the management of progressive glioblastoma : a systematic review and evidence-based clinical practice guideline.

Authors:  Timothy Charles Ryken; Nafi Aygun; Johnathan Morris; Marin Schweizer; Rajeshwari Nair; Cassandra Spracklen; Steven N Kalkanis; Jeffrey J Olson
Journal:  J Neurooncol       Date:  2014-04-09       Impact factor: 4.130

9.  Safety and efficacy of concomitant chemotherapeutic wafers and iodine-125 seeds for recurrent glioblastoma.

Authors:  Andrew L Ko; Kathleen R Fink; Keith M Stelzer; Daniel L Silbergeld
Journal:  Surg Neurol Int       Date:  2012-11-20

Review 10.  Iodine-125 brachytherapy for brain tumours--a review.

Authors:  Silke B Schwarz; Niklas Thon; Katharina Nikolajek; Maximilian Niyazi; Joerg-Christian Tonn; Claus Belka; Friedrich-Wilhelm Kreth
Journal:  Radiat Oncol       Date:  2012-03-06       Impact factor: 3.481

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.